Ipsen inks a string of deals in expansion effort

France's Ipsen is buying out Tercica in a $404 million deal, one of three new pacts designed to make Ipsen a billion-dollar a year player in the U.S. Ipsen will pay $9 a share for every share of Tercica it doesn't already own. That's more than double Tercica's $4.41 a share close yesterday. Like a lot of developers, Tercica's been losing money. But the biotech recently launched Somatuline for acromegaly, a pituitary gland disorder.

In a separate deal, Ipsen is buying out Vernalis' U.S. subsidiary, gaining the North American rights to Apokyn. And it inked a deal to acquire Octagen's OBI-1, which is being developed to treat hemophilia. The Octagen deal includes $10.5 million upfront and up to $26 million in milestones.

Taken together, Ipsen says the new acquisitions will position Ipsen to become a significant commercial player in the U.S.

- read Ipsen's release for more

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.